The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children

Vaccine

Volumn 29, Issue 38, 2011, Pages 6636-6640

  Okike, Ifeanyichukwu O ^a   Yung, Chee ^b   Ladhani, Shamez ^a,b   Oeser, Clarissa ^a   Bennett, Aisleen ^c   Doerholt, Katja ^c   Storey, Sharon ^c   Donaghy, Sheila ^c   Butter, Nigel ^a   Hoschler, Katja ^b   Sheasby, Liz ^b   Heath, Paul T ^a   Miller, Elizabeth ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

H1N1; HIV; Immunogenicity; Immunosuppression; Swine flu

Indexed keywords

ANTIRETROVIRUS AGENT; INFLUENZA VACCINE;

ADOLESCENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMAGGLUTINATION INHIBITION; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFLUENZA A (H1N1); MALE; OUTPATIENT; PANDEMIC; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STANDARD; STATISTICAL SIGNIFICANCE; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ALPHA-TOCOPHEROL; ANTIBODIES, VIRAL; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; FEMALE; GREAT BRITAIN; HEMAGGLUTINATION INHIBITION TESTS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA VACCINES; MALE; POLYSORBATES; SQUALENE; VACCINATION; VIRAL LOAD;

EID: 80051672999     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.103     Document Type: Article

References (41)

1. Neuzil K.M., Zhu Y., Griffin M.R., Edwards K.M., Thompson J.M., Tollefson S.J., et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis 2002, 185(January (2)):147-152.
2. Rojo J.C., Ruiz-Contreras J., Fernandez M.B., Marin M.A., Folgueira L. Influenza-related hospitalizations in children younger than three years of age. Pediatr Infect Dis J 2006, 25(July (7)):596-601.
3. Poehling K.A., Edwards K.M., Weinberg G.A., Szilagyi P., Staat M.A., Iwane M.K., et al. The underrecognized burden of influenza in young children. N Engl J Med 2006, 355(July (1)):31-40.
4. Iskander M., Booy R., Lambert S. The burden of influenza in children. Curr Opin Infect Dis 2007, 20(June (3)):259-263.
5. Zanetti A.R., Amendola A., Besana S., Boschini A., Tanzi E. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine 2002, 20(December (Suppl. 5)):B29-B32.
6. CDC. HIV/AIDS. Surveillance report 1997;9(2):1-43.
7. Madhi S.A., Schoub B., Simmank K., Blackburn N., Klugman K.P. Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1. J Pediatr 2000, 137(July (1)):78-84.
8. RCPCH. Immunisation of the immunocompromised child. Best practice statement; 2002.
9. CDC Prevention and control of influenza: recommendations of the advisory committee on immunisation practices (ACIP). Morbidity Mortality Weekly Report MMWR 2001, 50(RR-4):1-44.
10. Amendola A., Pariani E., Vigano A., Erba P., Zappa A., Giacomet V., et al. Influenza surveillance in a cohort of HIV-infected children and adolescents immunized against seasonal influenza. Vaccine 2010, 28(March (15)):2700-2704.
11. Tanzi E., Esposito S., Bojanin J., Amendola A., Trabattoni D., Pariani E., et al. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. J Med Virol 2006, 78(April (4)):440-445.
12. Zuccotti G.V., Zenga A., Durando P., Massone L., Bruzzone B., Sala D., et al. Immunogenicity and tolerability of a trivalent virosomal influenza vaccine in a cohort of HIV-infected children. J Int Med Res 2004, 32(September-October (5)):492-499.
13. Weinberg A., Song L.Y., Walker R., Allende M., Fenton T., Patterson-Bartlett J., et al. Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children. J Acquir Immune Defic Syndr 2010, 55(October (2)):189-196.
14. Esposito S., Tagliaferri L., Daleno C., Valzano A., Picciolli I., Tel F., et al. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. Vaccine 2011, 29(February (8)):1677-1682.
15. Vigano A., Zuccotti G.V., Pacei M., Erba P., Castelletti E., Giacomet V., et al. Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 48(July (3)):289-296.
16. Montoya C.J., Toro M.F., Aguirre C., Bustamante A., Hernandez M., Arango L.P., et al. Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy. Mem Inst Oswaldo Cruz 2007, 102(June (4)):501-508.
17. Chadwick E.G., Chang G., Decker M.D., Yogev R., Dimichele D., Edwards K.M. Serologic response to standard inactivated influenza vaccine in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1994, 13(March (3)):206-211.
18. Ho D.D. HIV-1 viraemia and influenza. Lancet 1992, 339(June (8808)):1549.
19. Ramilo O., Hicks P.J., Borvak J., Gross L.M., Zhong D., Squires J.E., et al. T cell activation and human immunodeficiency virus replication after influenza immunization of infected children. Pediatr Infect Dis J 1996, 15(March (3)):197-203.
20. Fuller J.D., Craven D.E., Steger K.A., Cox N., Heeren T.C., Chernoff D. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis 1999, 28(March (3)):541-547.
21. Keller M., Deveikis A., Cutillar-Garcia M., Gagajena A., Elkins K., Plaeger S., et al. Pneumococcal and influenza immunization and human immunodeficiency virus load in children. Pediatr Infect Dis J 2000, 19(July (7)):613-618.
22. de Carvalho A.P., Dutra L.C., Tonelli E. Influenza vaccination in HIV infected children: immunologic and viral load changes. J Pediatr (RioJ) 2003, 79(January-February (1)):29-40.
23. Perez-Padilla R., de la Rosa-Zamboni D., Ponce de Leon S., Hernandez M., Quinones-Falconi F., Bautista E., et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009, 361(August (7)):680-689.
24. CDC Outbreak of swine-origin influenza A (H1N1) virus infection - Mexico, March-April 2009. Morbidity and Mortality Weekly Report MMWR 2009, 58(17):467-470.
25. WHO. Influenza A (H1N1) - Update 14.
26. Waddington C.S., Walker W.T., Oeser C., Reiner A., John T., Wilkins S., et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010, 340:c2649.
27. A(H1N1) swine flu influenza: phase two of the vaccination programme; children over 6months and under 5 years: dosage schedule update. Department of Health; 2009.
28. Donaldson L., Beasley C., Ridge K. The H1N1 swine flu vaccination programme 2009-2010 2009, Department of Health.
29. Ellis J.S., Zambon M.C. Molecular analysis of an outbreak of influenza in the United Kingdom. Eur J Epidemiol 1997, 13(June (4)):369-372.
30. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361(December (25)):2424-2435.
31. Hardelid P., Andrews N., Hoschler K., Baguelin E.S., Waight M.P., et al. Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza AH1N1 2009. Health Technol Assess 2010, 14(55):115-192.
32. Amendola A., Boschini A., Colzani D., Anselmi G., Oltolina A., Zucconi R., et al. Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users. J Med Virol 2001, 65(December (4)):644-648.
33. Lyall E.G., Charlett A., Watkins P., Zambon M. Response to influenza virus vaccination in vertical HIV infection. Arch Dis Child 1997, 76(March (3)):215-218.
34. Lederman H.M., Williams P.L., Wu J.W., Evans T.G., Cohn S.E., McCutchan J.A., et al. Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J Infect Dis 2003, 188(December (12)):1794-1803.
35. Vesikari T., Pellegrini M., Karvonen A., Groth N., Borkowski A., O'Hagan D.T., et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009, 28(July (7)):563-571.
36. Pirofski L.A., Casadevall A. Use of licensed vaccines for active immunization of the immunocompromised host. Clin Microbiol Rev 1998, 11(January (1)):1-26.
37. Yerly S., Wunderli W., Wyler C.A., Kaiser L., Hirschel B., Suter S., et al. Influenza immunization of HIV-1-infected patients does not increase HIV-1 viral load. AIDS 1994, 8(October (10)):1503-1504.
38. Tasker S.A., Treanor J.J., Paxton W.B., Wallace M.R. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Int Med 1999, 131(September (6)):430-433.
39. Macias J., Pineda J.A., Leal M., Abad M.A., Delgado J., Rosa R., et al. HIV-1 plasma viremia not increased in patients receiving highly active antiretroviral therapy after influenza vaccination. Eur J Clin Microbiol Infect Dis 2001, 20(January (1)):46-48.
40. Jackson C.R., Vavro C.L., Valentine M.E., Pennington K.N., Lanier E.R., Katz S.L., et al. Effect of influenza immunization on immunologic and virologic characteristics of pediatric patients infected with human immunodeficiency virus. Pediatr Infect Dis J 1997, 16(February (2)):200-204.
41. WHO. Weekly epidemiological record, No. 5, 29 January 2010.